Truist Financial Corp Lowers Holdings in Eli Lilly and Company $LLY

Truist Financial Corp trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 357,383 shares of the company’s stock after selling 19,695 shares during the period. Truist Financial Corp’s holdings in Eli Lilly and Company were worth $272,682,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Laurel Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $8,827,714,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Eli Lilly and Company by 87.2% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock worth $898,238,000 after purchasing an additional 536,679 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to a development and commercialization deal worth up to $1.12 billion with Germany’s Seamless Therapeutics to target hearing‑loss treatments using Seamless’s gene‑editing platform — a sizable near‑term R&D/clinical collaboration that expands Lilly’s pipeline and long‑term growth optionality. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Analyst and trade commentary highlights Lilly’s expanding oncology and AI investments (including a high‑profile Nvidia collaboration reported previously), which support expectations for continued top‑line and pipeline growth beyond GLP‑1 drugs. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Neutral Sentiment: Lilly reports expected earnings activity this week and investor pieces debate valuation after strong recent gains — earnings and guidance will be a near‑term catalyst but market reaction depends on execution vs. lofty expectations. Eli Lilly and Company (LLY) Expected to Announce Earnings on Wednesday
• Neutral Sentiment: Lilly completed a Phase 1/2 readout update for pirtobrutinib, moving that BTK inhibitor program forward — clinical progress supports pipeline value but will require further data to shift commercial outlook materially. Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program has named Lilly products for its next negotiation round, increasing the risk of mandated price reductions for covered medicines and potential margin pressure. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Data show Novo Nordisk more than doubled U.S. advertising spend behind Wegovy and Ozempic vs. Lilly’s GLP‑1 ads in 1H–3Q25, signaling aggressive marketing that could weigh on Lilly’s market share and growth assumptions for weight‑loss products. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Hospital groups are urging regulators to block a new Lilly 340B claims‑data submission policy, creating regulatory friction and possible reputational/headwind risks with payers and providers. AHA Urges HRSA to Stop Eli Lilly’s New Policy on 340B Hospitals From Going into Effect

Analyst Ratings Changes

LLY has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Berenberg Bank lifted their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research note on Tuesday, December 2nd. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, December 16th. HSBC restated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $1,173.91.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,038.23 on Wednesday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm has a market cap of $981.52 billion, a P/E ratio of 50.79, a P/E/G ratio of 0.80 and a beta of 0.35. The firm’s 50 day moving average price is $1,058.15 and its 200-day moving average price is $885.09. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.